FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+19.09%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.5B
AUM Growth
+$2.5B
(+17%)
Cap. Flow
+$203M
Cap. Flow
% of AUM
8.14%
Top 10 Holdings %
Top 10 Hldgs %
59.89%
Holding
57
New
8
Increased
13
Reduced
5
Closed
4
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$155M |
| 2 |
Ascendis Pharma
ASND
|
$19.9M |
| 3 |
Alkermes
ALKS
|
$16.1M |
| 4 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$11.7M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$11.6M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$24M |
| 2 |
Vaxcyte
PCVX
|
$18.3M |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$16.1M |
| 4 |
Applied Therapeutics
APLT
|
$10.7M |
| 5 |
PepGen
PEPG
|
$6.84M |
Sector Composition
| 1 | Healthcare | 99.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Nuvation Bio
NUVB
$1.08B
| $2.79M | 0.11% |
+1,218,236
| New | +$2.79M |
|
52
Aclaris Therapeutics
ACRS
$223M
| $304K | 0.01% |
264,377
| – | – |
|
|
PVLA
53
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $267K | 0.01% |
+15,942
| New | +$267K |
|
|
CERE
54
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-393,000
| Closed | -$16.1M |
|
55
Metagenomi
MGX
$67.2M
| – | – |
-245,692
| Closed | -$1M |
|
|
56
Applied Therapeutics
APLT
$73.7M
| – | – |
-2,286,135
| Closed | -$10.7M |
|
57
AN2 Therapeutics
ANTX
$35.3M
| – | – |
-2,088,889
| Closed | -$4.49M |
|